Mersana Therapeutics, Inc. Deferred Offering Costs
Mersana Therapeutics, Inc. had Deferred Offering Costs of $2.91 million as of 2017-06-30, per its 10-Q filed 2017-08-11.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2018-03-28
- 2017-06-30: Deferred Offering Costs $2.91M.
- 2016-12-31: Deferred Offering Costs $60.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2017-06-30 | $2.91M 10-Q · filed 2017-08-11 |
| 2016-12-31 | $60.00K 10-K · filed 2018-03-28 |